David Avigan

18.3k citations

208 papers · 7.5k indexed · 2 hit papers · h-index 42

Impact in

Hematology top 0.2%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology

Papers in

Hematology 104
- Multiple Myeloma Research and Treatments 65
- Hematopoietic Stem Cell Transplantation 25
- Acute Myeloid Leukemia Research 18
Immunology 112
- Immunotherapy and Immune Responses 75
- Immune Cell Function and Interaction 38
- T-cell and B-cell Immunology 33

Co-authors: Jacalyn Rosenblatt Donald Küfe Robin Joyce Keisuke Ito Pier Paolo Pandolfi Zekui Wu Baldev Vasir Jianlin Gong
Journals: Blood (72 papers)Journal of Clinical Oncology (22 papers)Biology of Blood and Marrow Transplantation (12 papers)Bone Marrow Transplantation (7 papers)British Journal of Haematology (5 papers)
Partner nations: United States Israel Canada

In The Last Decade

David Avigan

205 papers receiving 7.3k citations

Hit Papers

align trajectories log scale

A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance 2012 · 556 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Nature Medicine
2011 New England Journal of Medicine

Peers

Countries citing papers authored by David Avigan

Since Specialization

Citations

This map shows the geographic impact of David Avigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Avigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Avigan more than expected).

Fields of papers citing papers by David Avigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Avigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Avigan. The network helps show where David Avigan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Avigan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Avigan Line = papers co-authored together David Avigan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire Nature Communications ·Giulia Cheloni, Dimitra Karagkouni, Yered Pita-Juárez, Daniela Torres, SHENG-CHAO MA, 文子若尾, Shreya Gowda, Руслан Мади, Nicola Olivato, Kathrine S Rallis, Brodie Miles, The Hop Hoang, Jenny Kim, Mike Mattie, Jacalyn Rosenblatt, Ioannis S. Vlachos, David Avigan	2025	0
2	Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in All Patients Clinical Lymphoma Myeloma & Leukemia ·Matthew J. Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud Gaballa, M. Swilling, Хасан С. Захраи, Kamalika Banerjee, Anand Rotte, Christopher R. Heery, David Avigan, Andrzej Jakubowiak, Michael Bishop	2024	2
3	Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy International Journal of Hematology ·Н. Михалюк, David Avigan	2023	13
4	Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study Leukemia & lymphoma ·John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham S. Kanate, Pier Luigi Zinzani, Jacob D. Bitran, Hervé Ghesquières, Stephen J. Schuster, Mohammed Z.H. Farooqui, Patricia Marinello, Nancy L. Bartlett	2022	12
5	Personalized tumor vaccine for pancreatic cancer Cancer Immunology Immunotherapy ·II D. Glass, Ling Huang, 韩吉旺, Dina Stroopinsky, Monu U. Ragashe, RW Witt, 文子若尾, Karina Anugrahwati, John D. Keown, Giulia Cheloni, Daniela Torres, Donald Küfe, Jacalyn Rosenblatt, Manuel Hidalgo, Senthil K. Muthuswamy, David Avigan	2022	11
6	Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo Clinical Cancer Research ·Eleni Anastasiadou, Anita G. Seto, Xuan Beatty, Melanie Hermreck, Maud-Emmanuelle Gilles, Dina Stroopinsky, Lauren Pinter‐Brown, Linda Pestano, Cinzia Marchese, David Avigan, Pankaj Trivedi, Diana M. Escolar, Aimee L. Jackson, Frank J. Slack	2020	110
7	Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013 British Journal of Haematology ·Vincent Ribrag, David Avigan, Damian J. Green, Trisha M. Wise‐Draper, Juan G. Posada, Ravi Vij, Ying Zhu, Mohammed Z.H. Farooqui, Patricia Marinello, David S. Siegel	2019	63
8	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma Molecular Cancer Therapeutics ·Salvia Jain, Abigail Washington, Rebecca Karp Leaf, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Dina Stroopinsky, Athalia R. Pyzer, Leandra Cole, Myrna Nahas, Arie Apel, Jacalyn Rosenblatt, Jon Arnason, Donald Küfe, David Avigan	2017	10
9	Dendritic Cell Therapies for Hematologic Malignancies Molecular Therapy — Methods & Clinical Development ·Matthew Weinstock, Jacalyn Rosenblatt, David Avigan	2017	42
10	Collaboration in Cancer Trials (October 26–27, 2015) The Oncologist ·Michel Sadelain, David Avigan, Priscilla K. Brastianos, Leif W. Ellisen, Alan D. D’Andrea, Lee Zou, Rakesh K. Jain, Sridhar Ramaswamy, Geoffrey M. Wahl	2015	2
11	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma Blood ·Salvia Jain, Dina Stroopinsky, Yin Li, Jacalyn Rosenblatt, Maroof Alam, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Kristen Palmer, Maxwell Coll, Hasan Rajabi, Athalia R. Pyzer, Michal Bar‐Natan, Katarina Luptakova, Jon Arnason, Robin Joyce, Donald Küfe, David Avigan	2015	28
12	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial Blood ·Daniel J. DeAngelo, Kristen E. Stevenson, Donna Neuberg, Lewis B. Silverman, Karen K. Ballen, Julie Asch, Yasser Abou Mourad, Kristjan Paulson, Matthew D. Seftel, David Avigan, Julie Bergeron, Stephen Couban, William Blum, John M. Storring, Martha Wadleigh, David P. Steensma, Jeffrey G. Supko, Stephen E. Sallan, Richard M. Stone	2015	37
13	MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells Cancer Research ·Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, Heidi Mills, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon Arnason, Caterina Nardella, James D. Levine, Robin Joyce, Ilene Galinsky, Yoram Reiter, Richard M. Stone, Pier Paolo Pandolfi, Donald Küfe, David Avigan	2013	41
14	Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells Cancer Research ·Deepak Raina, Rehan Ahmad, Maya Datt Joshi, Yin Li, Zekui Wu, Takeshi Kawano, Baldev Vasir, David Avigan, Surender Kharbanda, Donald Küfe	2009	125
15	Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells The Journal of Immunology ·Baldev Vasir, Zekui Wu, Keith Crawford, Jacalyn Rosenblatt, Corrine Zarwan, Jenny Fernanda Enríquez Chugá, Donald Küfe, David Avigan	2008	41
16	MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells Cancer Research ·Takeshi Kawano, Masaki Ito, Deepak Raina, Zekui Wu, Jacalyn Rosenblatt, David Avigan, Richard M. Stone, Donald Küfe	2007	34
17	Dendritic Cells Induce MUC1 Expression and Polarization on Human T Cells by an IL-7-Dependent Mechanism The Journal of Immunology ·Baldev Vasir, David Avigan, Zekui Wu, Keith Crawford, Terry Cheng, Jian Ren, Donald Küfe	2005	26
18	Cutting Edge: A Major Fraction of Human Bone Marrow Lymphocytes Are Th2-Like CD1d-Reactive T Cells That Can Suppress Mixed Lymphocyte Responses The Journal of Immunology ·Mark A. Exley, Syed Muhammad Tahir, Olivia Cheng, Angela Shaulov, Robin Joyce, David Avigan, Robert Sackstein, Steven P. Balk	2001	127
19	Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity The Journal of Immunology ·Jianlin Gong, Najmosama Nikrui, Dongshu Chen, Shigeo Koido, Zekui Wu, Yasuhiro Tanaka, Stephen A. Cannistra, David Avigan, Donald Küfe	2000	184
20	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors Cancer ·David Avigan, Paul G. Richardson, Anthony Elias, George D. Demetri, Michael Shapiro, Lowell E. Schnipper, Catherine Wheeler	1998	28

About David Avigan

David Avigan is a scholar working on Hematology, Immunology, Oncology, Cancer Research and Genetics, having authored 208 papers that have together received 7.5k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (75 papers), Multiple Myeloma Research and Treatments (65 papers), CAR-T cell therapy research (51 papers), Immune Cell Function and Interaction (38 papers), T-cell and B-cell Immunology (33 papers), Hematopoietic Stem Cell Transplantation (25 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Acute Myeloid Leukemia Research (18 papers). The work is most often cited by research in Hematology (2.6k citations), Immunology (3.7k citations), Oncology (2.9k citations), Cancer Research (702 citations) and Molecular Biology (3.0k citations). David Avigan has collaborated with scholars based in United States, Israel and Canada. Frequent co-authors include Jacalyn Rosenblatt, Donald Küfe, Robin Joyce, Keisuke Ito, Pier Paolo Pandolfi, Zekui Wu, Baldev Vasir, Jianlin Gong, Kenneth C. Anderson and Ugo Ala. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact